STRATA Skin Sciences appoints Erica Jordan as CEO, aiming to enhance commercial success and expand access to dermatologic therapies.
Quiver AI Summary
STRATA Skin Sciences, Inc. has appointed Erica Jordan as its new Chief Executive Officer, effective July 12, 2026. Jordan, an experienced leader in the healthcare industry, is expected to drive the company's growth and success, building on its established clinical outcomes and expansive reimbursement coverage. STRATA Chairperson Dr. Uri Geiger expressed appreciation for outgoing CEO Dr. Dolev Rafaeli's contributions and highlighted Jordan's ability to enhance sales operations and expand market presence. Previously, Jordan held senior roles at Revance Therapeutics and other notable companies, bringing a strong background in commercial strategy and operations. STRATA is focused on innovative laser therapies for dermatologic conditions and emphasizes partnerships that facilitate access for more practices and patients.
Potential Positives
- STRATA Skin Sciences appointed Erica Jordan as CEO, who has a proven record in expanding and transforming sales operations in large markets.
- Ms. Jordan's focus will be on scaling the commercial organization, increasing access to their innovative dermatologic therapies for more practices and patients.
- STRATA has established critical elements for commercial success, including proven clinical outcomes and established reimbursement, which Ms. Jordan aims to leverage.
- The company’s unique Partnership Program offers a favorable fee-per-treatment cost structure, enhancing accessibility for dermatology practices and potentially improving patient outcomes.
Potential Negatives
- The appointment of a new CEO may raise concerns about leadership stability and continuity in corporate strategy, particularly after the long tenure of former CEO Dr. Dolev Rafaeli.
- Ms. Jordan's previous role at Revance Therapeutics may lead to scrutiny regarding her ability to replicate or improve upon past performance and results in her new position at STRATA.
- Forward-looking statements indicate potential risks and uncertainties that might affect the company’s future performance, which could be seen as a red flag for investors.
FAQ
Who has been appointed CEO of STRATA Skin Sciences?
Erica Jordan has been appointed as the Chief Executive Officer of STRATA Skin Sciences, effective July 12, 2026.
What is Erica Jordan's background in the industry?
Erica Jordan is a strategic commercial leader with extensive experience in sales operations and marketing across major healthcare organizations.
What will be Erica Jordan's focus as CEO of STRATA?
Her focus will be on scaling the commercial organization to increase access to STRATA's therapies for more practices and patients.
What products does STRATA Skin Sciences offer?
STRATA offers innovative dermatologic treatment products, including the XTRAC® excimer laser, VTRAC® lamp systems, and TheraClear®X Acne Therapy System.
How does STRATA's partnership program benefit practices?
The partnership program provides a fee per treatment cost structure, on-site training, maintenance, and advertising support to dermatology practices.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SSKN Revenue
$SSKN had revenues of $9.3M in Q4 2025. This is a decrease of -2.97% from the same period in the prior year.
You can track SSKN financials on Quiver Quantitative's SSKN stock page.
You can access data on SSKN stock through the Quiver Quantitative API.
$SSKN Hedge Fund Activity
We have seen 0 institutional investors add shares of $SSKN stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- 22NW, LP removed 536,995 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $155,674
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 403,917 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $117,095
- RENAISSANCE TECHNOLOGIES LLC removed 63,830 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $18,504
- GEODE CAPITAL MANAGEMENT, LLC removed 18,896 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,477
- APOLLON WEALTH MANAGEMENT, LLC removed 15,105 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,378
- TWO SIGMA SECURITIES, LLC removed 15,093 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,375
- CREATIVE PLANNING removed 10,016 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,903
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
HORSHAM, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, has appointed industry veteran Erica Jordan as Chief Executive Officer, effective July 12, 2026.
STRATA chairperson Dr. Uri Geiger stated, “Erica has a proven record of expanding and transforming sales operations in large markets. We look forward to collaborating closely with Erica as she brings STRATA into its next era and translates the historical expanded CPT Code coverage into commercial success. I also want to thank Dr. Dolev Rafaeli for his long tenure as CEO and building the foundation of Strata Skin Sciences”
Erica Jordan is a strategic commercial leader with a focus on partnering with providers to enable care and improve business practices. She is well versed in revitalizing organizations by increasing revenue, scaling operations, expanding markets, transforming sales and commercial teams, and launching innovative products and services in diverse markets. She has demonstrated a long-standing commitment to cross-functional collaboration and meaningful customer engagement, excelling in aligning teams with shared goals and navigating matrix organizations to achieve corporate objectives.
"STRATA has what many companies spend years trying to build: proven clinical outcomes, established reimbursement, and a commercial partnership model that removes the capital barrier for dermatology practices," said Ms. Jordan. "My focus will be on scaling the commercial organization so that more practices — and ultimately more patients who are candidates for these therapies — have access to them."
Prior to joining STRATA, Ms. Jordan served as Chief Commercial Officer for Revance Therapeutics, spearheading sales, marketing (B2B and B2C), operations, corporate communications, investor relations, corporate strategy, and business excellence in domestic and international markets. Prior, she served as Metrex president at Envista Holdings (former Danaher Company). She has held leadership positions within the sales and marketing functions at leading organizations, including Change Healthcare (now part of Optum), Philips Healthcare, Fujifilm Medical, Siemens Medical Solutions, and GE Healthcare. She holds a Bachelor of Science degree in Marketing from the University of Wisconsin- Milwaukee.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC ® excimer laser, VTRAC ® lamp systems, and the TheraClear ® X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. STRATA Skin Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
Contact
STRATA Skin Sciences, Inc.
5 Walnut Grove Drive, Suite 140, Horsham, PA 19044
(215) 619-3200 | [email protected] | strataskinsciences.com